Background: Frostbite injury creates an ischemic, hypoxic, and acidic microenvironment that often triggers severe oxidative stress and inflammation. Current therapeutic approaches are limited by low drug delivery efficiency and an inability to adequately regulate multiple pathological pathways. Although oxyresveratrol (OR) exhibits excellent antioxidant and anti-inflammatory activities, its application is hampered by poor aqueous solubility and low stability. Methods: We constructed Oxyresveratrol@Zeolitic Imidazolate Framework-8 nanoparticles (OR@ZIF-8) and further embedded them in a sodium hyaluronate (HA) matrix to form an OR@ZIF-8@HA composite hydrogel. The physicochemical properties and pH-responsive drug release behavior of the system were characterized. Its antioxidant activity, ability to promote cell migration, and capacity to modulate macrophage polarization were evaluated in cellular assays. The therapeutic efficacy was further investigated using a mouse frostbite model, with wound repair analyzed via histological staining. Results: The OR@ZIF-8 nanoparticles achieved a cumulative release rate of 75.46 ± 3.68% under acidic conditions within 36 h. In vitro experiments demonstrated that the formulation significantly scavenged TNF-α and IL-6, by 161.85 ± 19.43% and 125.37 ± 12.65%, respectively, and increased the level of IL-10 by 44.97 ± 4.57%. In a scratch assay, it promoted wound healing, achieving a closure rate of 97.55 ± 2.77% after 36 h. In vivo studies revealed that the OR@ZIF-8@HA treatment group achieved a wound healing rate of 96.14 ± 4.12% on day 14. Conclusions: The OR@ZIF-8@HA composite hydrogel effectively overcomes the limitations of OR application via intelligent pH-responsive delivery. Through synergistic multi-mechanistic actions, it significantly accelerates frostbite wound healing, offering a novel and efficient therapeutic strategy for frostbite management.

Camellia petelotii (Merr.) Sealy (Jinhuacha, JHC) is a rare plant species native to Guangxi, China, and northern Vietnam, renowned for its significant ornamental, nutritional, and medicinal properties. To date, 177 chemical constituents have been isolated and identified from JHC, including Flavonoids, Terpenoids, Steroids, Phenylpropanoids, Essential oils, Alkaloids, and Organic acids. Among these, Quercetin, Kaempferol, Luteolin, Catechin, Oleanolic acid, and Camelliaside A are the primary bioactive compounds. The JHC exhibits diverse pharmacological activities, including hypolipidemic and hypoglycemic effects, anti-inflammatory, antioxidant, antibacterial, antidepressant, and antitumor properties. Studies have demonstrated that extracts of JHC effectively inhibit pancreatic lipase (PL) and cholesterol esterase (CEase), with median inhibitory concentrations (IC50) values of 320 μg/mL and 200 μg/mL, respectively. Additionally, the extracts show strong free radical scavenging activity, with 2,2-Diphenyl-1-picrylhydrazyl (DPPH) and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical clearance rates reaching 84.61% and 95.51%, respectively. Clinical applications indicate that JHC Hypoglycemic Capsules achieve a total effective rate of 93.33% in the adjunctive treatment of patients with type 2 diabetes. Nevertheless, the quality control markers and the precise mechanisms underlying certain pharmacological effects of JHC remain to be fully elucidated. This paper systematically reviews current advances in the study of the chemical constituents and pharmacological effects of JHC, and further proposes future research directions, aiming to provide a scientific foundation for the in-depth investigation of its active constituents and mechanisms of action.

Objective: To systematically evaluate the potential of Saussurea involucrata cultures (SICs) against high-altitude illness under hypobaric hypoxia and establish a progressive experimental evidence chain covering acute hypoxia tolerance enhancement and acute/chronic hypoxic injury protection. Methods: A tiered experimental strategy was employed. Key findings were derived from primary rat models of acute (5500 m, 8 h) and chronic intermittent (5500 m, 8 h/d, 4–8 weeks) hypobaric hypoxia. A mouse acute tolerance model (10,000 m lethality, closed-system endurance) provided supplementary verification. Comprehensive analyses included survival, hemorheology, multi-organ function, and core mechanistic indicators of endothelial function and oxidative stress. Diamox, Rhodiola, and Compound Danshen Dripping Pills served as positive controls. Normoxic/hypoxic blank groups served as negative controls. Results: SICs significantly enhanced acute hypoxia tolerance in mice. In the rat models, SICs demonstrated dose-dependent and selective regulation of the endothelial–oxidative stress/hemorheology axis. Specifically, it downregulated endothelin-1, upregulated nitric oxide, enhanced total antioxidant capacity, and improved chronic hypoxia-induced blood hyperviscosity. Medium doses showed consistent optimal efficacy. SICs had limited effects on macroscopic organ remodeling. Conclusions: The core protective effect of SICs lies in enhancing hypoxic tolerance and selectively modulating the interconnected pathways of endothelial function, oxidative stress, and microcirculatory health. This mechanistic profile supports its potential as a preventive or early adjuvant intervention for high-altitude illness, providing a systematic preclinical foundation for translational development.

Investigation of the roots of Tripterygium wilfordii Hook. f. resulted in the isolation of nine sesquiterpene pyridine alkaloids (SPAs), including four previously undescribed compounds 1–4. The structures of all compounds were elucidated by extensive spectroscopic analysis, including NMR and HRESIMS. In particular, compound 1 was found to possess an unprecedented cage-like ether moiety, representing the first report of such a structural feature within this class of alkaloids. All isolated compounds were evaluated for their anti-inflammatory activity using a lipopolysaccharide (LPS)-induced RAW264.7 macrophage model. Compounds 1, 2, and 4 exhibited significant inhibition of nitric oxide (NO) production, with IC₅₀ values of 7.14 ± 1.89, 8.55 ± 0.37, and 14.76 ± 0.39 μM. Furthermore, compounds 1 and 2 suppressed the secretion of key pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, in the same cellular model. These results not only enhanced the structural diversity of SPAs identified from T. wilfordii, but also highlight their potential as promising anti-inflammatory lead compounds.